Dr Catherine Shu (Columbia University Irving Medical Center, New York, NY, USA) discusses the findings of the CHRYSALIS-2 study, which supports the use of amivantamab in certain groups of patients with advanced non-small-cell lung cancer (NSCLC) and represents a chemotherapy-free regimen.
The abstract ‘Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2’ (Abstract: 9006) was presented at the ASCO annual meeting, 3-7 June 2022.
Questions
1. Could you tell us a little about combined therapy with amivantamab and Lazertinib, and the clinical evidence in support of its use?
2. What were the aims and design of the CHRYSALIS-2 study?
3. Which patients were included in cohort A and what were the efficacy findings in this study?
4. What was the safety profile of the combination and what is the importance of this combination?
Disclosures: Catherine A. Shu is a member of the advisory board for AstraZeneca, Mirati Therapeutics, Genentech and Janssen.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
